Schroten-Loef Caroline, de Ridder Corrina M A, Reneman Suzanne, Crezee Marije, Dalgleish Angus, Todryk Stephen M, Bangma Chris H, Kraaij Robert
Erasmus MC, Department of Urology, Josephine Nefkens Institute, Rotterdam, The Netherlands.
Cancer Immunol Immunother. 2009 Mar;58(3):373-81. doi: 10.1007/s00262-008-0560-z. Epub 2008 Jul 19.
A panel of cytokine-secreting RM-9 prostate cancer cells were tested as whole cell vaccines to determine their capacity to evoke an anti-prostate cancer immune response. In our model, vaccines secreting mGM-CSF or mIL-7 resulted in the highest increase in circulating T lymphocytes after vaccination, prolonged survival and, in a proportion of animals, tumor-free survival. Anti-tumor effects were more evident after a subcutaneous RM-9 challenge than after an intraprostatic challenge. However, when the RM-9/mGM-CSF cell line was used as intraprostatic tumor challenge, protection after RM-9/mIL-7 vaccination was restored.
一组分泌细胞因子的RM-9前列腺癌细胞作为全细胞疫苗进行测试，以确定它们引发抗前列腺癌免疫反应的能力。在我们的模型中，分泌mGM-CSF或mIL-7的疫苗在接种后导致循环T淋巴细胞增加最多，延长了生存期，并且在一部分动物中实现了无瘤生存期。皮下接种RM-9后的抗肿瘤效果比前列腺内接种后更明显。然而，当使用RM-9/mGM-CSF细胞系进行前列腺内肿瘤攻击时，RM-9/mIL-7疫苗接种后的保护作用得以恢复。
